Serum concentrations of DKK-1 decrease in patients with multiple myeloma responding to anti-myeloma treatment

Area of Science:

• Oncology
• Bone Biology
• Medical Biochemistry

Background:

• Multiple myeloma (MM) is characterized by lytic bone destruction due to dysregulated bone remodeling.
• Myeloma cells secrete Dickkopf-1 (DKK-1), a protein that inhibits osteoblast precursor differentiation.
• Elevated serum DKK-1 levels are observed in MM patients compared to those with monoclonal gammopathy of undetermined significance (MGUS).

Purpose of the Study:

• To investigate the impact of various multiple myeloma treatment regimens on serum DKK-1 levels.
• To correlate changes in serum DKK-1 with treatment response in MM patients.
• To explore the potential of DKK-1 as a biomarker for MM treatment efficacy.

Main Methods:

• Serum DKK-1 levels were measured at baseline and post-therapy in 101 MM patients.
• Patients received treatments including bortezomib, thalidomide, lenalidomide, adriamycin and dexamethasone (AD), or high-dose chemotherapy with autologous stem cell transplantation (HDCT + ASCT).
• DKK-1 levels were analyzed in relation to treatment regimens and patient response (complete or partial remission).

Main Results:

• MM patients exhibited significantly higher baseline serum DKK-1 than MGUS patients.
• Significant decreases in serum DKK-1 were observed following treatment with bortezomib, lenalidomide, AD, and AD + HDCT + ASCT.
• A significant reduction in DKK-1 was exclusively observed in patients achieving remission, irrespective of the treatment regimen.

Conclusions:

• Serum DKK-1 levels decrease in multiple myeloma patients who respond to therapy.
• Myeloma cells are identified as the primary source of circulating DKK-1.
• These findings support DKK-1 as a potential biomarker for treatment response and suggest anti-DKK-1 therapies for MM.